OBJECTIVE: In many patients with obsessive-compulsive disorder (OCD), residual symptoms persist despite a clinically meaningful response. The objective of this study was to examine whether addition of behavior therapy would augment treatment outcome in these patients. METHOD: Ninety-six patients with DSM-IV OCD who had responded to 3 months of drug treatment were randomly assigned to either receive addition of behavior therapy or continue on drug treatment alone for 6 months. Patients who continued on drug treatment alone eventually received addition ofbehavior therapy for 6 months. Data were gathered from October 1998 to June 2002. RESULTS:OCD patients who received addition ofbehavior therapy showed a greater improvement in obsessive-compulsive symptoms (Yale-Brown Obsessive Compulsive Scale [Y-BOCS] score change = -3.9 in the completers sample) than those who continued on drug treatment alone (Y-BOCS score change = +3.9 for completers). Significantly more patients who received addition of behavior therapy were in remission compared with those who continued on drug treatment alone (p < .0001 for completers). Patients who received behavior therapy after 6 months of drug treatment alone showed a nonsignificant decline in obsessive-compulsive symptoms (Y-BOCS score change = -2.7 for completers); however, the remission rate found in this group was comparable to the remission rate found in the group of patients receiving addition of behavior therapy directly after responding to drug treatment. CONCLUSION: The results indicate that addition of behavior therapy is beneficial for patients who have responded to drug treatment. The data also suggest that the effect is greater when behavior therapy is added immediately after attainment of the drug response.
RCT Entities:
OBJECTIVE: In many patients with obsessive-compulsive disorder (OCD), residual symptoms persist despite a clinically meaningful response. The objective of this study was to examine whether addition of behavior therapy would augment treatment outcome in these patients. METHOD: Ninety-six patients with DSM-IV OCD who had responded to 3 months of drug treatment were randomly assigned to either receive addition of behavior therapy or continue on drug treatment alone for 6 months. Patients who continued on drug treatment alone eventually received addition of behavior therapy for 6 months. Data were gathered from October 1998 to June 2002. RESULTS:OCDpatients who received addition of behavior therapy showed a greater improvement in obsessive-compulsive symptoms (Yale-Brown Obsessive Compulsive Scale [Y-BOCS] score change = -3.9 in the completers sample) than those who continued on drug treatment alone (Y-BOCS score change = +3.9 for completers). Significantly more patients who received addition of behavior therapy were in remission compared with those who continued on drug treatment alone (p < .0001 for completers). Patients who received behavior therapy after 6 months of drug treatment alone showed a nonsignificant decline in obsessive-compulsive symptoms (Y-BOCS score change = -2.7 for completers); however, the remission rate found in this group was comparable to the remission rate found in the group of patients receiving addition of behavior therapy directly after responding to drug treatment. CONCLUSION: The results indicate that addition of behavior therapy is beneficial for patients who have responded to drug treatment. The data also suggest that the effect is greater when behavior therapy is added immediately after attainment of the drug response.
Authors: Martin E Franklin; Jeffrey Sapyta; Jennifer B Freeman; Muniya Khanna; Scott Compton; Daniel Almirall; Phoebe Moore; Molly Choate-Summers; Abbe Garcia; Aubrey L Edson; Edna B Foa; John S March Journal: JAMA Date: 2011-09-21 Impact factor: 56.272
Authors: Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Jonathan D Huppert; Shawn Cahill; Michael J Maher; Carmen P McLean; James Bender; Sue M Marcus; Monnica T Williams; Jamie Weaver; Donna Vermes; Page E Van Meter; Carolyn I Rodriguez; Mark Powers; Anthony Pinto; Patricia Imms; Chang-Gyu Hahn; Raphael Campeas Journal: JAMA Psychiatry Date: 2013-11 Impact factor: 21.596
Authors: Edna B Foa; Helen Blair Simpson; David Rosenfield; Michael R Liebowitz; Shawn P Cahill; Jonathan D Huppert; James Bender; Carmen P McLean; Michael J Maher; Raphael Campeas; Chang-Gyu Hahn; Patricia Imms; Anthony Pinto; Mark B Powers; Carolyn I Rodriguez; Page E Van Meter; Donna Vermes; Monnica T Williams Journal: J Clin Psychiatry Date: 2015-04 Impact factor: 4.384
Authors: Helen Blair Simpson; Eva Petkova; Jianfeng Cheng; Jonathan Huppert; Edna Foa; Michael R Liebowitz Journal: J Psychiatr Res Date: 2007-09-24 Impact factor: 4.791
Authors: Pim Cuijpers; Marit Sijbrandij; Sander L Koole; Gerhard Andersson; Aartjan T Beekman; Charles F Reynolds Journal: World Psychiatry Date: 2014-02 Impact factor: 49.548
Authors: Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Deborah Roth Ledley; Jonathan D Huppert; Shawn Cahill; Donna Vermes; Andrew B Schmidt; Elizabeth Hembree; Martin Franklin; Raphael Campeas; Chang-Gyu Hahn; Eva Petkova Journal: Am J Psychiatry Date: 2008-03-03 Impact factor: 18.112
Authors: Edna B Foa; Helen Blair Simpson; Michael R Liebowitz; Mark B Powers; David Rosenfield; Shawn P Cahill; Raphael Campeas; Martin Franklin; Chang-Gyu Hahn; Elizabeth A Hembree; Jonathan D Huppert; Andrew B Schmidt; Donna Vermes; Monnica T Williams Journal: J Clin Psychiatry Date: 2013-05 Impact factor: 4.384